ReCode Therapeutics has raised $80 million in Series B financing that it will use in large part to fund clinical development of inhaled therapies for cystic fibrosis and primary ciliary dyskinesia (PCD), the company said. According to the announcement, funds will also be used for expanding the company’s pipeline and for adding manufacturing capabilities.
Earlier this year, ReCode announced promising results from preclinical studies of its nebulized lipid nanoparticle (LNP) DNAI1 mRNA therapy for the treatment of PCD, including the ability of the formulations to restore ciliary activity. According to the company website, the therapy for PCD is in development for inhalation only; the therapy for CF is being developed for delivery by IV or inhalation.
ReCode President and CEO David Lockhart said, “ReCode is working to unleash the power of genetic medicine by delivering therapies with our novel LNP platform, which has the potential to reach across a broad spectrum of diseases involving multiple organs and tissues. The significant capital secured from such a respected group of investors, known for backing innovative biotechnology companies, enables us to accelerate delivery of impactful medicines to thousands of patients with genetic respiratory diseases in need of options, including those with CF and PCD.”
Read the ReCode Therapeutics press release.
